WPD Pharmaceuticals Inc. (WBIO.CN) Research

WPD Pharmaceuticals Inc., a biopharmaceutical company based in Vancouver, Canada, specializes in the research and advancement of therapeutic products for oncology and infectious diseases. The company's diverse drug development pipeline features multiple promising candidates: WPD101 and WPD103 are both in pre-clinical stages, targeting brain cancers, including glioblastoma and glioblastoma multiforme respectively. Also in pre-clinical development is WPD102, aimed at Uveal Melanoma. In more advanced clinical stages, Berubicin is undergoing Phase 1 trials for glioblastoma, while WP1066, also in Phase 1 clinical trials, is being investigated for central nervous system tumors, pancreatic cancer, and ocular tumors. Additionally, the pipeline includes WP1732 for pancreatic cancer and WP1220 for cutaneous T-cell lymphoma. Annamycin is currently in Phase I/II clinical trials for acute myeloid leukemia (AML) and is also being explored for lung metastasis.

Market snapshot

Symbol
WBIO.CN
Price
$0.07
Day change
-63.16%
Market cap
$324.8K
P/E ratio
-99.29x
52-week range
0.07-1.125
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Albert Labs International Corp. (ABRT.CN)
  • Bioasis Technologies Inc. (BTI.V)
  • ChitogenX Inc. (CHGX.CN)
  • Biocure Technology Inc. (CURE.CN)
  • Restart Life Sciences Corp. (HEAL.CN)
  • Lowell Farms Inc. (LOWL.CN)
  • Nirvana Life Sciences Inc. (NIRV.CN)
  • NanoSphere Health Sciences Inc. (NSHS.CN)

Open WPD Pharmaceuticals Inc. (WBIO.CN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.